Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,197 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Only Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide (LY3298176) in Healthy Participants

NCT03375463
View directory record Official record
Conditions
Healthy
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 3, 2026, 8:43 AM EDT
Recruiting Phase 1 Interventional

Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT

NCT05095532
View directory record Official record
Conditions
Chronic Pancreatitis, Mesenchymal Stem Cells
Interventions
Bone marrow-derived mesenchymal stem cells, Placebo
Biological · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Not listed Phase 1Phase 2 Interventional

Metformin in Patients With Fragile X

NCT04141163
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Metformin, Placebo oral tablet
Drug
Lead sponsor
Rowan University
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stratford, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations

NCT04120363
View directory record Official record
Conditions
Caloric Restriction, Exercise, Sleep
Interventions
Testosterone Undecanoate, Sesame Oil
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Not applicable Interventional Results available

Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks

NCT00329732
View directory record Official record
Conditions
Migraine
Interventions
0.5% bupivicaine and 2% lidocaine, Saline placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09

NCT02027155
View directory record Official record
Conditions
Anesthesia
Interventions
AR09 solution, placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

NCT02626026
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tirabrutinib, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
9
States / cities
Sacramento, California • Miami, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Results available

Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression

NCT00305578
View directory record Official record
Conditions
Bipolar Depression
Interventions
Memantine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 3, 2026, 8:43 AM EDT
Not listed Phase 2 Interventional

Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain

NCT05470608
View directory record Official record
Conditions
Osteoarthritis, Knee Pain
Interventions
SL-1002, Placebo
Drug
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
35 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Greenwood Village, Colorado • Washington D.C., District of Columbia • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional

TAK-329 Glucose Clamp Study

NCT01311076
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
TAK-329, Insulin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2012 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Safety Study in Humans of a Single Dose of CPG 52364

NCT00547014
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2009 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis

NCT00601484
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
PF-04383119, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Peoria, Arizona • Fresno, California • Glendora, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

H3N2 M2SR in Pediatric Population

NCT03553940
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine, Placebo, Quadrivalent MDCK Inactivated Influenza Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

NCT02809118
View directory record Official record
Conditions
Hearing Loss, Idiopathic Sudden Sensorineural
Interventions
AM-111 0.4 mg/ml, AM-111 0.8 mg/ml, Placebo
Drug · Other
Lead sponsor
Auris Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
38
States / cities
Birmingham, Alabama • Escondido, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

NCT03775278
View directory record Official record
Conditions
Otherwise Healthy Overweight or Obese
Interventions
PHP-303, Placebo
Drug · Other
Lead sponsor
pH Pharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2Phase 3 Interventional

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

NCT02231008
View directory record Official record
Conditions
Smith-Magenis Syndrome, Circadian
Interventions
tasimelteon, placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
3 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Santa Monica, California • Baltimore, Maryland • Chevy Chase, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to an Investigational Dengue Type 2 Vaccine

NCT01073306
View directory record Official record
Conditions
Dengue Virus
Interventions
Investigational Vaccine for Dengue Virus Subtype 2, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277743
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Placebo (for Dupilumab)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

NCT02079168
View directory record Official record
Conditions
Keloid
Interventions
RXI-109, Placebo
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

NCT04164758
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Pimavanserin, Placebo, Quetiapine
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

NCT03713684
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Efpeglenatide SAR439977, Placebo, Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

NCT02331433
View directory record Official record
Conditions
Schizophrenia
Interventions
APN1125, Placebo
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 3, 2026, 8:43 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

NCT05231785
View directory record Official record
Conditions
Early-Onset Alzheimer Disease
Interventions
ALN-APP, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
La Jolla, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Not applicable Interventional

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

NCT05573685
View directory record Official record
Conditions
Rheumatoid Arthritis, Diabetic Neuropathy, Fibromyalgia, Irritable Bowel Syndrome
Interventions
DiNaMo Study App, Placebo App
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 3, 2026, 8:43 AM EDT